ArticleHead & face medicine2025
FTO enhances OSCC progression via m⁶A-dependent stabilization of PKM2 mRNA through YTHDF2 modulation.
Article in Head & face medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Ubiquitination and NOncology letters · 2026Review
- Reader-dependent functional duality of FTO: a context-switching node at the intersection of immune evasion and therapeutic resistance.Frontiers in immunology · 2026Review
- Immunometabolic reprogramming in rheumatoid arthritis: the epitranscriptomic role of N6-methyladenosine in innate and adaptive immunity.Frontiers in immunology · 2026Review
- miR-101/METTL3 axis induces autophagy by interrupting FOXG1/EIF3J-AS1 binding in gliomas.Cell death & disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectivesOral squamous cell carcinoma (OSCC) is a highly aggressive malignancy with poor prognosis and limited treatment options. N6-methyladenosine (m⁶A) modification represents a pivotal layer of epitranscriptomic regulation in cancer. Fat mass and obesity-associated protein (FTO), an m⁶A demethylase, has been implicated in several malignancies. While FTO's involvement in OSCC is emerging, its regulation of glycolytic metabolism remains uncharacterized. This study aimed to investigate the biological function of FTO in OSCC and determine whether it modulates PKM2 expression through an m⁶A-dependent mechanism involving YTHDF2. MATERIALS AND
methodsFTO expression was analyzed in OSCC tissues by immunohistochemistry and Western blotting. Functional assays were performed in SCC25 and CAL27 cells with stable FTO knockdown or overexpression to assess proliferation, migration, invasion, and glycolytic activity. Global m⁶A levels, RNA-protein associations, and mRNA stability were examined using dot blot, RIP-qPCR, and actinomycin D treatment. NF-κB pathway activation was evaluated by Western blotting. In vivo tumorigenicity was assessed using xenograft models.
resultsFTO was markedly upregulated in OSCC tissues and correlated with aggressive clinical features. Silencing FTO attenuated malignant phenotypes and glycolytic flux. Mechanistically, FTO stabilized PKM2 mRNA by reducing YTHDF2-mediated degradation via m⁶A demethylation. FTO expression also coincided with enhanced NF-κB signaling activity.
conclusionThese findings define an FTO/m⁶A/YTHDF2/PKM2 axis that promotes OSCC progression through glycolytic reprogramming and tumor growth, highlighting a potential metabolic vulnerability for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.